MRK vs DXCM
By Alex · Tickerpine
Merck & Company, Inc. vs DexCom, Inc., side by side — the numbers that matter, in plain English. No “winner” hype; you decide.
| Metric | MRK | DXCM |
|---|---|---|
| Price | $132.92 | $90.80 |
| Market cap | $327.94B | $34.26B |
| P/E ratio | 106.3 | 35.9 |
| ROE | 6.96% | 38.49% |
| Profit margin | 4.77% | 20.12% |
| Revenue growth | 5.10% | 13.10% |
| Dividend yield | 2.56% | — |
| Beta | 0.21 | 1.41 |
Green = the more favorable figure for that metric (lower P/E, higher ROE, margin, growth and yield). Not a recommendation.
MRK vs DXCM in plain English
- MRK is the bigger company — about 9.6× the market cap of DXCM.
- DXCM is cheaper on earnings (P/E 35.9 vs 106.3).
- DXCM earns a higher return on equity (38% vs 7%).
- DXCM is growing revenue faster (13% vs 5%).
- MRK pays a dividend (2.56%) while the other effectively doesn't.
How would $1,000 have done in each?
MRK return calculator
See what $1,000 in Merck & Company, Inc. would be worth today.
DXCM return calculator
See what $1,000 in DexCom, Inc. would be worth today.
Figures from public market data, may be delayed. Comparison is informational only — not investment advice.